[{"address1": "The Schr\u00f6dinger Building", "address2": "Oxford Science Park", "city": "Oxford", "zip": "OX4 4GE", "country": "United Kingdom", "phone": "44 18 6581 8941", "website": "https://www.exscientia.ai", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy. It is also involved in the development of EXS4318, a PKC-theta inhibitor, under Phase 1 clinical trial for inflammation and immunology indications; EXS74539, a LSD1 inhibitor, under preclinical studies for SCLC, AML, and potential additional indications; EXS73565, a MALT1 inhibitor, under preclinical studies for multiple hematology indications; and DSP-0038, currently in Phase 1 studies. The company has collaboration agreements with Merck KGaA, Bristol Myers Squibb, Sanofi, Bill & Melinda Gates Foundation, Charit\u00e9 \u0096 Universit\u00e4tsmedizin Berlin, Rallybio, and GT Apeiron Therapeutics. Exscientia plc was founded in 2012 and is headquartered in Oxford, the United Kingdom.", "fullTimeEmployees": 483, "companyOfficers": [{"maxAge": 1, "name": "Dr. David  Hallett Ph.D.", "age": 54, "title": "Chief Scientific Officer, Interim CEO, Principal Executive Officer & Executive Director", "yearBorn": 1969, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ben R. Taylor", "age": 46, "title": "CFO, Chief Strategy Officer & Executive Director", "yearBorn": 1977, "fiscalYear": 2023, "totalPay": 532012, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Michael  Krams M.D.", "age": 62, "title": "Chief Medical Officer", "yearBorn": 1961, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Eileen  Jennings-Brown", "title": "Chief Information Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Sara  Sherman", "title": "Vice President of Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Dan  Ireland", "title": "Vice President of Legal & Company Secretary", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Parker  Moss", "title": "Executive Vice President of Corporate Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Caroline  Rowland", "title": "Chief People Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Richard  Law", "title": "Chief Business Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. John P. Overington Ph.D.", "title": "Chief Data Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 5.94, "open": 5.87, "dayLow": 5.73, "dayHigh": 5.99, "regularMarketPreviousClose": 5.94, "regularMarketOpen": 5.87, "regularMarketDayLow": 5.73, "regularMarketDayHigh": 5.99, "beta": 0.827, "forwardPE": -4.070922, "volume": 405818, "regularMarketVolume": 405818, "averageVolume": 753814, "averageVolume10days": 1071800, "averageDailyVolume10Day": 1071800, "bid": 5.71, "ask": 5.76, "bidSize": 100, "askSize": 600, "marketCap": 723928768, "fiftyTwoWeekLow": 4.17, "fiftyTwoWeekHigh": 9.12, "priceToSalesTrailing12Months": 36.054024, "fiftyDayAverage": 6.1998, "twoHundredDayAverage": 6.158425, "currency": "USD", "enterpriseValue": 379800320, "floatShares": 92583112, "sharesOutstanding": 126120000, "sharesShort": 3230890, "sharesShortPriorMonth": 3439455, "sharesShortPreviousMonthDate": 1706659200, "dateShortInterest": 1709164800, "sharesPercentSharesOut": 0.025899999, "heldPercentInsiders": 0.26503, "heldPercentInstitutions": 0.25244, "shortRatio": 3.89, "shortPercentOfFloat": 0.0542, "impliedSharesOutstanding": 126120000, "bookValue": 2.83, "priceToBook": 2.0282686, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -145963008, "trailingEps": -1.49, "forwardEps": -1.41, "pegRatio": 0.06, "enterpriseToRevenue": 18.915, "enterpriseToEbitda": -2.337, "52WeekChange": 0.015929222, "SandP52WeekChange": 0.29191303, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "EXAI", "underlyingSymbol": "EXAI", "shortName": "Exscientia Plc", "longName": "Exscientia plc", "firstTradeDateEpochUtc": 1633095000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "338b7c25-91d3-36d5-9c38-0f21999063b2", "messageBoardId": "finmb_408328234", "gmtOffSetMilliseconds": -14400000, "currentPrice": 5.74, "targetHighPrice": 10.0, "targetLowPrice": 7.0, "targetMeanPrice": 8.67, "targetMedianPrice": 9.0, "recommendationMean": 2.7, "recommendationKey": "hold", "numberOfAnalystOpinions": 3, "totalCash": 363048992, "totalCashPerShare": 2.879, "ebitda": -162516992, "totalDebt": 18923000, "quickRatio": 6.131, "currentRatio": 6.223, "totalRevenue": 20079000, "debtToEquity": 5.32, "revenuePerShare": 0.162, "returnOnAssets": -0.18794, "returnOnEquity": -0.34978, "freeCashflow": -116438248, "operatingCashflow": -117602000, "revenueGrowth": -0.643, "grossMargins": -0.36476, "operatingMargins": -17.89959, "financialCurrency": "GBP", "trailingPegRatio": null, "__fetch_time": "2024-03-27"}]